Transmitted drug resistance to integrase based first-line HIV antiretroviral regimens in the Mediterranean Europe.
Adolfo de SalazarLaura ViñuelaAna FuentesElisa TeyssouCharlotte CharpentierSidonie Lambert-NiclotEsther Serrano-CondeMarta PingarilhoLavinia FabeniAnne De MonteKarl SteficCarlo Federico PernoAntonio AguileraIker FalcesRafael DelgadoSandra FernandesIsabel DiogoPerpetua GomesDimitrios ParaskevisMaria-Mercedes SantoroFrancesca Ceccherini-SilbersteinAnne-Geneviève MarcelinFederico GarciaPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
We present the most recent data on TDR to integrase based first-line regimens in Europe. Given the low prevalence of CRR to second generation integrase inhibitors and to first-line NRTIs, in the years 2018-2021 it is unlikely that newly diagnosed PWH in MeditRes countries would present with baseline resistance to a first-line regimen based on second generation integrase inhibitors.